8月 15, 2023
  • 诺华以 32 亿美元预付款完成对Chinook Therapeutics 的收购。Chinook Therapeutics是一家专注于临床阶段的生物制药公司 
  • 本次收购包括两项处于III期研究的 IgA肾病（IgAN）资产：口服内皮素 A 受体拮抗剂阿曲生坦（atrasentan ）和抗 APRIL 单克隆抗体 zigakibart
  • 此项交易与诺华专注于创新药物的战略完全契合，将显著扩展诺华在肾脏疾病领域的产品组合，并补充现有的研发管线。

诺华日前宣布已完成对 Chinook Therapeutics 的收购。Chinook Therapeutics是一家总部位于华盛顿州西雅图的生物制药公司，专注于肾脏疾病精准治疗药物的研究、开发和商业化。此项交易金额高达 35 亿美元。

Chinook的管线包括两款处于临床研发阶段用于治疗IgA肾病的药物阿曲生坦和zigakibart（BION-1301），以及早期研发项目。阿曲生坦是一种口服内皮素A受体拮抗剂（ERA），目前正处于治疗IgA肾病的III期研发阶段，预计将在2023年第四季度获得关键临床数据，前期研究已显示其可显著减少蛋白尿。阿曲生坦同时也处于治疗其它罕见肾脏疾病的早期研发阶段。Zigakibart（BION-1301）是一种皮下给药的抗APRIL单克隆抗体，已于 2023 年 7 月进入治疗IgA肾病 的 III期临床研究。

诺华集团首席执行官万思瀚 (Vas Narasimhan) 表示：很高兴完成这项重要的交易，期待通过整合资源和专业知识，进一步推动这些前景广阔的治疗方法的开发，造福罹患罕见的、严重慢性肾病的患者。欢迎 Chinook 团队加入诺华大家庭，共同携手扩展肾脏疾病产品组合，创想医药未来。

Chinook的股东将获得每股 40美元的现金（总计 32 亿美元）。如果达到特定监管里程碑，Chinook的股东还将根据或有价值权（CVR）获得最多每股4 美元的现金。这意味着Chinook的股东可额外获得的或有对价总额最高可达 3 亿美元。


关于诺华中国
诺华公司中文名取意“承诺中华”，即通过不断创新的产品和服务，提高中国人民的健康水平和生活质量。自1987年以来，诺华已有近100款创新药及新适应症在华获批。诺华在中国的业务包括诺华创新药物（中国）与山德士（中国），并在北京、上海和江苏设立了研发机构。诺华在中国拥有超过8000名员工。如需更多信息，敬请访问诺华中文网站：www.novartis.com.cn。

 

This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “potential,” “can,” “will,” “plan,” “may,” “could,” “would,” “expect,” “anticipate,” “seek,” “look forward,” “believe,” “committed,” “investigational,” “pipeline,” “launch,” or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for atresentan or zigakibart, the acquisition of Chinook Therapeutics, Inc. or regarding potential future revenues from atresentan or zigakibart. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that atresentan or zigakibart will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Neither can there be any guarantee that the expected benefits or synergies from this transaction will be achieved in the expected timeframe, or at all, nor can there be any guarantee that atresentan or zigakibart will be commercially successful in the future. In particular, our expectations regarding atresentan or zigakibart or the transaction described in this press release could be affected by, among other things, expected revenues, cost savings, synergies and other benefits from the transaction might not be realized within the expected time frames or at all and costs or difficulties relating to integration matters, including but not limited to employee retention, might be greater than expected; business disruption may occur following or in connection with the acquisition; the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases such as COVID-19; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.